WO2005052130A3 - Genes nrbp utilises en tant que modificateurs de la voie rac et procedes d'utilisation associes - Google Patents

Genes nrbp utilises en tant que modificateurs de la voie rac et procedes d'utilisation associes Download PDF

Info

Publication number
WO2005052130A3
WO2005052130A3 PCT/US2004/039708 US2004039708W WO2005052130A3 WO 2005052130 A3 WO2005052130 A3 WO 2005052130A3 US 2004039708 W US2004039708 W US 2004039708W WO 2005052130 A3 WO2005052130 A3 WO 2005052130A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
rac
nrbps
modifiers
rac pathway
Prior art date
Application number
PCT/US2004/039708
Other languages
English (en)
Other versions
WO2005052130A2 (fr
Inventor
Lisa C Kadyk
George Ross Francis
Kim Lickteig
Original Assignee
Exelixis Inc
Lisa C Kadyk
George Ross Francis
Kim Lickteig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Lisa C Kadyk, George Ross Francis, Kim Lickteig filed Critical Exelixis Inc
Publication of WO2005052130A2 publication Critical patent/WO2005052130A2/fr
Publication of WO2005052130A3 publication Critical patent/WO2005052130A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des gènes NRBP humains identifiés en tant que modulateurs de la voie RAC, qui constituent par conséquent des agents thérapeutiques destinés au traitement de troubles associés à une fonction déficiente de RAC. L'invention concerne également des procédés d'identification de modulateurs de RAC, qui consistent à cribler des agents qui modulent l'activité de gènes NRBP.
PCT/US2004/039708 2003-11-24 2004-11-23 Genes nrbp utilises en tant que modificateurs de la voie rac et procedes d'utilisation associes WO2005052130A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52454103P 2003-11-24 2003-11-24
US60/524,541 2003-11-24

Publications (2)

Publication Number Publication Date
WO2005052130A2 WO2005052130A2 (fr) 2005-06-09
WO2005052130A3 true WO2005052130A3 (fr) 2006-01-26

Family

ID=34632904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/039708 WO2005052130A2 (fr) 2003-11-24 2004-11-23 Genes nrbp utilises en tant que modificateurs de la voie rac et procedes d'utilisation associes

Country Status (1)

Country Link
WO (1) WO2005052130A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DE LANGHE S ET AL: "Interaction of the small GTPase Rac3 with NRBP, a protein with a kinase-homology domain", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 9, 2002, pages 451 - 459 *
HOOPER J.D. ET AL: "Cloning of the cDNA and localization of the gene encoding human NRBP, a ubiquitously expressed, multidomain putative adapter protein", GENOMICS, vol. 66, 2000, pages 113 - 118, XP004449339 *
LIM R. ET AL: "MADM,a novel adaptor protein that mediates phosphorylation of the 14-3-3 binding site of myeloid leukemia factor 1", J. BIOL. CHEM., vol. 277, no. 42, 2002, pages 40997 - 41008, XP002993146 *
LUTCHMAN M. ET AL: "Dematin interacts with the Ras-guanine nucleotide exchange factor Ras-GRF2 and modulates mitogen-activated protein kinase pathways.", EUR. J. BIOCHEM., vol. 269, January 2002 (2002-01-01), pages 638 - 649, XP002993148 *
SORDELLA R. ET AL: "Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis", CELL, vol. 113, April 2003 (2003-04-01), pages 147 - 158, XP002993147 *

Also Published As

Publication number Publication date
WO2005052130A2 (fr) 2005-06-09

Similar Documents

Publication Publication Date Title
WO2003083047A3 (fr) Genes mp53 en tant que modificateurs de la voie des proteines p53 et methodes d'utilisation
WO2005016287A3 (fr) Prkwnk utilises en tant que modificateurs de la voie rac et methodes d'utilisation associees
WO2003051905A3 (fr) Taojik utilises en tant que modificateurs de la voie beta-catenine et procedes d'utilisation associes
WO2006036613A3 (fr) Genes mrac utilises en tant que modificateurs de la voie rac et procedes d'utilisation correspondants
WO2005002418A3 (fr) Mpten en tant que modulateurs du passage pten/igf et procedes d'utilisation
WO2004024882A3 (fr) Flj20647 utilise en tant que modificateur de la voie p21 et procedes d'utilisation associes
WO2005003297A3 (fr) Genes mpten utilises en tant que modificateurs de la voie pten/igf et procedes d'utilisation associes
WO2004013309A3 (fr) Papss comme modificateurs de la voie d'axin et procédés d'utilisation
WO2005090992A3 (fr) Genes mpten modifiant le trajet pten, et procedes d'utilisation
WO2004048538A3 (fr) Caseine kinases modifiant la voie rac et leurs procedes d'utilisation
WO2004005483A3 (fr) Adcy3s modificateurs de la voie p21 et methodes d'utilisation
WO2005017123A3 (fr) Mptens utilises comme modificateurs de la voie pten et procedes d'utilisation
WO2004015071A3 (fr) Genes csnk1gs utilises en tant que modificateurs de la voie p21 et procede d'utilisation associe
WO2004014301A3 (fr) Genes psmc utilises comme modificateurs du trajet retiniblastome (rb) et techniques d'utilisation
WO2004005486A3 (fr) Genes mp21 utilises comme modificateurs de la voie p21 et leurs procedes d'utilisation
WO2005052130A3 (fr) Genes nrbp utilises en tant que modificateurs de la voie rac et procedes d'utilisation associes
WO2005001026A3 (fr) Adenosines kinases en tant que modificateurs de la voie pten et leurs procedes d'utilisation
WO2004048541A3 (fr) Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants
WO2004083389A3 (fr) Genes mbcat utilises comme modificateurs de la voie de la beta-catenine et techniques d'utilisation
WO2003074725A3 (fr) Mbcat comme modificateurs du mecanisme d'action de la $g(b)-catenine et procedes d'utilisation correspondants
WO2004061123A3 (fr) Mbcat servant de modificateurs de la voie de beta-catenine et leurs procedes d'utilisation
WO2005017120A3 (fr) Mracs modificateurs de la voie rac et methodes d'utilisation
WO2005052134A3 (fr) Tau-tubuline kinases utilisees comme modificateurs de la voie de la beta-catenine et leurs procedes d'utilisation
WO2003074677A3 (fr) Mchk comme modulateurs du mecanisme d'action de chk et procedes d'utilisation
WO2003074673A3 (fr) Lgals tenant lieu de modificateurs de la voie de chk et leurs procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase